 Patients undergo leukapheresis and collection of peripheral blood mononuclear cells from which dendritic cells DC are generated and pulsed with carcinoembryonic antigen peptide 1-6D CAP 1-6D and CMV pp65 peptide. Patients are assigned to 1 of 2 vaccination cohorts. 